Document Detail

Diabetes mellitus adversely affects the outcomes of thrombolytic therapy in patients with acute myocardial infarction.
MedLine Citation:
PMID:  12934765     Owner:  NLM     Status:  MEDLINE    
This study was performed to evaluate whether coexistent diabetes mellitus has any adverse effect on the outcomes of thrombolytic therapy in patients with acute myocardial infarction. Although the early reperfusion rates were similar between the two groups of patients who had acute myocardial infarction with and without diabetes mellitus (42% vs 45.4%, p > 0.05), the results of late angiographic examination showed a significantly lower rate of patency in infarct-related coronary artery (defined as TIMI 3 flow) in diabetics compared to nondiabetics (28.9% vs 41.3%, p < 0.001). The global left ventricular function was also poorer in diabetics (left ventricular wall motion score was 18.6 +/- 7.3 in diabetics and 14.1 +/- 4.6 in nondiabetics, p < 0.01).
Hakan Tikiz; Ugur Tezcan; Mehmet Ileri; Yücel Balbay; Ramazan Atak; Emine Kütük
Related Documents :
2121015 - Comparison of coronary and myocardial morphologic findings in patients with and without...
12695445 - Are we underestimating the full potential of early thrombolytic treatment in patients w...
8770835 - The promise of new genetically engineered plasminogen activators.
2119665 - Safety and efficacy of repeat thrombolytic treatment after acute myocardial infarction.
3738555 - The impact of the family and lay others on care-seeking during life-threatening episode...
1673955 - Congestive heart failure in patients with normal left ventricular systolic function: a ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Angiology     Volume:  54     ISSN:  0003-3197     ISO Abbreviation:  Angiology     Publication Date:    2003 Jul-Aug
Date Detail:
Created Date:  2003-08-25     Completed Date:  2003-09-10     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0203706     Medline TA:  Angiology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  449-56     Citation Subset:  IM    
University of Celal Bayar, Department of Cardiology, Manisa, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cardiomyopathies / complications*,  drug therapy*,  physiopathology
Collateral Circulation / physiology
Coronary Angiography
Coronary Disease / radiography
Diabetes Complications*
Diabetes Mellitus / physiopathology
Fibrinolytic Agents / therapeutic use*
Middle Aged
Streptokinase / therapeutic use*
Thrombolytic Therapy*
Tissue Plasminogen Activator / therapeutic use*
Ventricular Function, Left / physiology
Reg. No./Substance:
0/Fibrinolytic Agents; EC 3.4.-/Streptokinase; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Assessment of adenosine-induced coronary steal in the setting of coronary occlusion based on the ext...
Next Document:  Power thrombectomy in acute ischemic coronary syndromes.